RSLS

Vyome Holdings, Inc. (RSLS) | Rumor.io

Vyome Holdings

RSLS

Attention (50-day avg)0%

Attention rank (50-day avg)—

Bullish sentiment (50-day avg)0%

Price to earnings ratio0.01

Market capitalization4.9M

Earnings per share-830.4

Dividend yield (TTM)—

Revenue (annual)8M

Net income (annual)-7.1M

Social

What share of all stock conversation is about RSLS?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% 0

Apr 10

ReShape Lifesciences has announced a partnership with Motion Informatics to bring AI-driven neurorehabilitation technology to the US market, expanding its weight loss and metabolic health solutions.
The company's short interest has increased, with over 400K shares shorted and a cost to borrow of 680%, indicating potential market pressure.
ReShape Lifesciences has been added to the Reg SHO fail-to-deliver list, which may indicate a high level of short selling activity.

Generated by AI

Sentiment

Of the messages about RSLS that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	84.62% +81.19
Bearish	—	—	—	15.38% -81.19

Bullish· Feb 3

$RSLS has seen a 300% increase in pre-market, indicating significant potential for growth.
The company's micro float has contributed to its volatility, making it a prime candidate for a short squeeze.
ReShape Lifesciences Inc. has demonstrated the ability to reverse split and increase its stock price, suggesting a possible repeat performance in the future.

Bearish· Feb 6

$RSLS has been heavily shorted, with many investors having to cover their positions, leading to significant price drops.
The company's decision to lower its pricing may not have been enough to prevent a price drop, potentially causing panic among investors.
The stock's volatility and tendency to drop significantly in a short period of time make it a high-risk investment, potentially leading to substantial losses for some investors.

Generated by AI

Topics

Of the messages about RSLS that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	—	—	—	0%
Announcements	—	—	—	100%
Controversies	—	—	—	0%
Earnings	—	—	—	0%
Macro	—	—	—	0%
Technical Analysis	—	—	—	0%

Announcements· Apr 21

ReShape Lifesciences Inc. (RSLS) has announced the pricing of a $2.5 million registered direct offering and concurrent private placement priced at-the-market.
The company will receive net proceeds of approximately $2.4 million from the registered direct offering and approximately $100,000 from the concurrent private placement.
The funds raised will be used for general corporate purposes, including working capital and other business objectives.

Technical Analysis· Feb 3

$RSLS has spiked from $46 to $21, with a possible reversal on the way at its 200-day MA.
The stock's 14.55 dip was sold at 30% at 16.45, with the rest held for higher action.
$RSLS's SMA10 crossed above SMA20 on the 5-minute chart, and its RSI has gone positive with an increase in volume.

Generated by AI

Community

Of the messages about RSLS, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	—	7.94%
Newcomers	—	—	—	92.06%

Regulars· Apr 17

$RSLS is experiencing a significant run-up, with heavy volume coming in, and could be a good candidate for a squeeze idea, potentially.
The stock has a low float, with only 0.5M shares available, and a high short float percentage of 19.3%, making it a potentially volatile and squeezable stock.
$RSLS has been in a downtrend since April 12, 2023, according to the momentum indicator, and its price has been fluctuating, with a 27% increase in the past day, and a 5.8% drop at 14:29.

Newcomers· Apr 19

Many new users are predicting a potential price run for $RSLS due to its low market capitalization and small float, citing comparisons to other stocks like $CXAI.
Some users are identifying $RSLS as a potential "next mover" among low-float stocks, with a target price range of $3.15 to $11.70, and suggesting that it could be the last of the low-float stocks to experience a price surge.
There is speculation that $RSLS may experience an explosive price increase in the coming weeks, potentially reaching $20-$40, with some users citing analyst price targets and others expressing optimism about the stock's prospects.

Generated by AI

News

ReShape Lifesciences® Announces Partial Adjournment of Special Meeting of Stockholders

Partial Adjournment for Proposal 2, Asset Sale Proposal, and Proposal 3, Charter Amendment Proposal; All Other Proposals Required for Merger Were Approved ...

1mo agoBarchart.com

Also Discussed

Investors talking about RSLS also mention

#	Name	Attention
1	OBLN - Obalon Therapeutics, Inc.	——
2	MRIN - Marin Software Incorporated	——
3	MTSL - Mer Telemanagement Solutions Ltd.	——
4	XELA - Exela Technologies, Inc.	——
5	Motorsport Games Inc. Class A Common StockMSGM	0%0
6	Virpax Pharmaceuticals Inc.VRPX	0%0
7	Sonoma Pharmaceuticals Inc.SNOA	0%0
8	Ensysce Biosciences, Inc. Common StockENSC	0%0
9	PEDEVCO Corp.PED	0%new
10	Revelation Biosciences Inc.REVB	0%0

Vyome Holdings, Inc.

Healthcare
Medical Devices

Vyome Holdings, Inc. is a clinical-stage biotechnology and specialty pharmaceutical company focused on developing next-generation therapeutic solutions for immuno-inflammatory diseases, including rare conditions with unmet medical needs. Operating within the healthcare sector under diversified biopharmaceuticals, the company engages in research and development of innovative pharmaceutical products. Vyome Holdings aims to address challenging diseases through advanced therapies, contributing to medical progress in immunology and rare disease treatment.

Website

Location

18 Technology Drive

Irvine, CA, 92618

United States

Social

What share of all stock conversation is about RSLS?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% 0

Apr 10

ReShape Lifesciences has announced a partnership with Motion Informatics to bring AI-driven neurorehabilitation technology to the US market, expanding its weight loss and metabolic health solutions.
The company's short interest has increased, with over 400K shares shorted and a cost to borrow of 680%, indicating potential market pressure.
ReShape Lifesciences has been added to the Reg SHO fail-to-deliver list, which may indicate a high level of short selling activity.

Generated by AI

Sentiment

Of the messages about RSLS that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	84.62% +81.19
Bearish	—	—	—	15.38% -81.19

Bullish· Feb 3

$RSLS has seen a 300% increase in pre-market, indicating significant potential for growth.
The company's micro float has contributed to its volatility, making it a prime candidate for a short squeeze.
ReShape Lifesciences Inc. has demonstrated the ability to reverse split and increase its stock price, suggesting a possible repeat performance in the future.

Bearish· Feb 6

$RSLS has been heavily shorted, with many investors having to cover their positions, leading to significant price drops.
The company's decision to lower its pricing may not have been enough to prevent a price drop, potentially causing panic among investors.
The stock's volatility and tendency to drop significantly in a short period of time make it a high-risk investment, potentially leading to substantial losses for some investors.

Generated by AI

Topics

Of the messages about RSLS that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	—	—	—	0%
Announcements	—	—	—	100%
Controversies	—	—	—	0%
Earnings	—	—	—	0%
Macro	—	—	—	0%
Technical Analysis	—	—	—	0%

Announcements· Apr 21

ReShape Lifesciences Inc. (RSLS) has announced the pricing of a $2.5 million registered direct offering and concurrent private placement priced at-the-market.
The company will receive net proceeds of approximately $2.4 million from the registered direct offering and approximately $100,000 from the concurrent private placement.
The funds raised will be used for general corporate purposes, including working capital and other business objectives.

Technical Analysis· Feb 3

$RSLS has spiked from $46 to $21, with a possible reversal on the way at its 200-day MA.
The stock's 14.55 dip was sold at 30% at 16.45, with the rest held for higher action.
$RSLS's SMA10 crossed above SMA20 on the 5-minute chart, and its RSI has gone positive with an increase in volume.

Generated by AI

Community

Of the messages about RSLS, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	—	7.94%
Newcomers	—	—	—	92.06%

Regulars· Apr 17

$RSLS is experiencing a significant run-up, with heavy volume coming in, and could be a good candidate for a squeeze idea, potentially.
The stock has a low float, with only 0.5M shares available, and a high short float percentage of 19.3%, making it a potentially volatile and squeezable stock.
$RSLS has been in a downtrend since April 12, 2023, according to the momentum indicator, and its price has been fluctuating, with a 27% increase in the past day, and a 5.8% drop at 14:29.

Newcomers· Apr 19

Many new users are predicting a potential price run for $RSLS due to its low market capitalization and small float, citing comparisons to other stocks like $CXAI.
Some users are identifying $RSLS as a potential "next mover" among low-float stocks, with a target price range of $3.15 to $11.70, and suggesting that it could be the last of the low-float stocks to experience a price surge.
There is speculation that $RSLS may experience an explosive price increase in the coming weeks, potentially reaching $20-$40, with some users citing analyst price targets and others expressing optimism about the stock's prospects.

Generated by AI

Vyome Holdings

Social

Apr 10

Bullish· Feb 3

Bearish· Feb 6

Announcements· Apr 21

Technical Analysis· Feb 3

Regulars· Apr 17

Newcomers· Apr 19

ReShape Lifesciences® Announces Partial Adjournment of Special Meeting of Stockholders

Also Discussed

Vyome Holdings, Inc.

Company Information

Location

ReShape Lifesciences® Announces Partial Adjournment of Special Meeting of Stockholders

Also Discussed

Social

Apr 10

Bullish· Feb 3

Bearish· Feb 6

Announcements· Apr 21

Technical Analysis· Feb 3

Regulars· Apr 17

Newcomers· Apr 19